921592-86-1 Usage
General Description
1-(5-amino-2-pyridinyl)-3-(R)-pyrrolidinol is a chemical compound that consists of a pyrrolidine ring attached to a pyridine ring with an amino group at the 5th position of the pyridine ring. It is a chiral compound, meaning it has a handedness or asymmetry in its molecular structure. This chemical has potential pharmaceutical applications, as it may have biological activity in the body due to its structure and interaction with biological systems. It is important to consider the chirality of 1-(5-amino-2-pyridinyl)-3-(R)-pyrrolidinol in pharmaceutical applications, as different enantiomers (mirror images) of chiral compounds can have different effects in the body. Understanding and controlling the chirality of this compound is important in drug development and medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 921592-86-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,1,5,9 and 2 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 921592-86:
(8*9)+(7*2)+(6*1)+(5*5)+(4*9)+(3*2)+(2*8)+(1*6)=181
181 % 10 = 1
So 921592-86-1 is a valid CAS Registry Number.
921592-86-1Relevant articles and documents
SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS
-
, (2013/03/26)
The invention relates to substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
THERAPEUTIC AGENTS
-
Page/Page column 26, (2010/11/25)
Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.